# Acadia Pharmaceuticals Inc. (ACAD) stock price

URL: https://funkfolio.com/stock/ACAD

> Acadia Pharmaceuticals Inc. (ACAD) trades at $18.17, is worth $3.14B, is priced at 8.6× earnings and scores 75/100. Valuation, financials and signals.

---

## Acadia Pharmaceuticals Inc. (ACAD)

Acadia Pharmaceuticals Inc. (ACAD) is a healthcare company (biotechnology) based in the United States. The share price is $18.17, down 2.68% on the day, which values the company at $3.14B. Price as of 17 Nov 2026, 17:41 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $18.17 −2.68% today
- **Market value:** $3.14B
- **P/E ratio:** 8.6× last 12 months
- **Forward P/E:** 16.7×
- **Funk Score:** 75/100
- **Against its own history:** Well below its usual price usual price $28.25
- **200-week average:** $21.55 16% below
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 17:41 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Acadia Pharmaceuticals Inc. in more detail

ACAD trades at 8.6× its last twelve months' earnings, 16.7× next year's expected earnings, 2.6× sales. Measured against its own history, the price is 36% below what its usual multiples would imply ($28.25) — well below its usual price. It sits 16% below its 200-week average of $21.55.

Over the last five fiscal years Acadia Pharmaceuticals Inc. has compounded revenue 19.4% a year. Its Funk Score is 75 out of 100 (financial strength 9.2, profitability 5.8, growth 9.9, value 5.1, each out of 10).

In its favour: Altman Z in the safe zone; Operating margin is expanding. Worth checking: Beneish M-score flags the accounts; Share count keeps rising.

1 of the superinvestors tracked here hold ACAD, including Julian and Felix Baker (5.4% of the portfolio).

### Superinvestors holding ACAD

1 of the investors tracked here report a position in their latest 13F filing.

- [Julian and Felix Baker Baker Bros. Advisors](https://funkfolio.com/gurus/baker-brothers) 5.44% of portfolio · $1.1B · added · Q2 2026

### Acadia Pharmaceuticals Inc. (ACAD): questions and answers

**What is ACAD's P/E ratio?**

Acadia Pharmaceuticals Inc. trades at 8.6× its last twelve months' earnings and 16.7× next year's expected earnings. At its fiscal year-ends over the past 3 years the P/E ranged from 3.1× to 13.5×, with a median of 11.6×.

**What is ACAD's PEG ratio?**

Acadia Pharmaceuticals Inc.'s PEG ratio is 50.86 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

**What is Acadia Pharmaceuticals Inc.'s market cap?**

Acadia Pharmaceuticals Inc. is valued at $3.14B at a share price of $18.17.

**Is ACAD overvalued or undervalued?**

Against its own history, ACAD is well below its usual price: the price is 36% below the $28.25 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is ACAD above its 200-week moving average?**

No. ACAD is 15.7% below its 200-week average of $21.55. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Acadia Pharmaceuticals Inc. growing?**

Over the last five fiscal years Acadia Pharmaceuticals Inc.'s revenue grew 19.4% a year; over ten years revenue grew 165.7% a year.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Acadia Pharmaceuticals Inc. (ACAD) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ACAD

Underlying data: Yahoo Finance; company filings with the SEC.
